{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:43:18Z","timestamp":1776868998128,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4113-3","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T08:48:43Z","timestamp":1518857323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma"],"prefix":"10.1186","volume":"18","author":[{"given":"Duneesha","family":"de Fonseka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Stadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Darby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Virgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick A.","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"4113_CR1","doi-asserted-by":"crossref","unstructured":"Chapman A, Mulrennan S, Ladd B, Muers MF: Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008, 63(5):435\u2013439.","DOI":"10.1136\/thx.2007.081430"},{"issue":"14","key":"4113_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4113_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","volume":"88","author":"P Beckett","year":"2015","unstructured":"Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer. 2015;88(3):344\u20138.","journal-title":"Lung Cancer"},{"issue":"10026","key":"4113_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","journal-title":"Lancet"},{"issue":"4","key":"4113_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabro","year":"2015","unstructured":"Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301\u20139.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"4113_CR6","doi-asserted-by":"publisher","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","volume":"9","author":"R Cornelissen","year":"2014","unstructured":"Cornelissen R, Lievense LA, Maat AP, Hendriks RW, Hoogsteden HC, Bogers AJ, Hegmans JP, Aerts JG. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS One. 2014;9(9):e106742.","journal-title":"PLoS One"},{"issue":"23","key":"4113_CR7","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","volume":"20","author":"R Hassan","year":"2014","unstructured":"Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O\u2019Shannessy DJ, Fatato P, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927\u201336.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4113_CR8","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","volume":"22","author":"DH Sterman","year":"2016","unstructured":"Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, et al. Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNalpha Combined with Chemotherapy. Clin Cancer Res. 2016;22(15):3791\u2013800.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4113_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","volume":"72","author":"GL Ceresoli","year":"2011","unstructured":"Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73\u20137.","journal-title":"Lung Cancer"},{"key":"4113_CR10","doi-asserted-by":"crossref","unstructured":"Serke M, Bauer T: Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2007, 25(18_suppl):18198\u201318198.","DOI":"10.1200\/jco.2007.25.18_suppl.18198"},{"key":"4113_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1745-6673-3-34","volume":"3","author":"A Xanthopoulos","year":"2008","unstructured":"Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schonfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol. 2008;3:34.","journal-title":"J Occup Med Toxicol"},{"issue":"7","key":"4113_CR12","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/cncr.23337","volume":"112","author":"PA Zucali","year":"2008","unstructured":"Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112(7):1555\u201361.","journal-title":"Cancer"},{"issue":"4","key":"4113_CR13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.2214\/AJR.05.0076","volume":"186","author":"SG Armato 3rd","year":"2006","unstructured":"Armato SG 3rd, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006;186(4):1000\u20136.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"4113_CR14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/bjc.2015.62","volume":"112","author":"CE Hooper","year":"2015","unstructured":"Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman NM, De Winton E, et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer. 2015;112(7):1175\u201382.","journal-title":"Br J Cancer"},{"issue":"2","key":"4113_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1378\/chest.14-0820","volume":"147","author":"JM Porcel","year":"2015","unstructured":"Porcel JM, Hernandez P, Martinez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147(2):502\u201312.","journal-title":"Chest"},{"issue":"9396","key":"4113_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","volume":"362","author":"BW Robinson","year":"2003","unstructured":"Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612\u20136.","journal-title":"Lancet"},{"key":"4113_CR17","doi-asserted-by":"crossref","unstructured":"Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer. 2017;","DOI":"10.1038\/bjc.2017.22"},{"issue":"3","key":"4113_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","volume":"82","author":"J Creaney","year":"2013","unstructured":"Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82(3):491\u20138.","journal-title":"Lung Cancer"},{"issue":"11","key":"4113_CR19","doi-asserted-by":"publisher","first-page":"e013324","DOI":"10.1136\/bmjopen-2016-013324","volume":"6","author":"S Tsim","year":"2016","unstructured":"Tsim S, Kelly C, Alexander L, McCormick C, Thomson F, Woodward R, Foster JE, Stobo DB, Paul J, Maskell NA, et al. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. BMJ Open. 2016;6(11):e013324.","journal-title":"BMJ Open"},{"issue":"10","key":"4113_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","volume":"179","author":"BD Grigoriu","year":"2009","unstructured":"Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med. 2009;179(10):950\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4113_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","volume":"17","author":"J Creaney","year":"2011","unstructured":"Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2011;17(5):1181\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4113_CR22","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","volume":"6","author":"K Hollevoet","year":"2011","unstructured":"Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, Germonpre P, Kellen E, Legrand C, Kishi Y, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011;6(11):1930\u20137.","journal-title":"J Thorac Oncol"},{"issue":"20","key":"4113_CR23","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","volume":"28","author":"P Wheatley-Price","year":"2010","unstructured":"Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O\u2019Sullivan B, et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010;28(20):3316\u201322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4113_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1378\/chest.11-0129","volume":"141","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P, Bosquee L, Legrand C, Kellen E, Kishi Y, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest. 2012;141(2):477\u201384.","journal-title":"Chest"},{"issue":"23\u201324","key":"4113_CR25","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","volume":"411","author":"MJ Duffy","year":"2010","unstructured":"Duffy MJ, Evoy D, McDermott EW. CA 15\u20133: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010;411(23\u201324):1869\u201374.","journal-title":"Clin Chim Acta"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4113-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T07:45:40Z","timestamp":1603871140000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4113-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4113"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4113-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"2 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients gave written informed consent and the trial was approved by the South West REC (Ref 08\/H0102\/11).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"199"}}